Market Place
Sourcing Support
Biocartis Partners With Mayo on Breast Cancer Gene Signatures
13 Jan 2026 //
PHARMIWEB
Biocartis NV: Partners With Mayo Clinic On Breast Cancer Gene
12 Jan 2026 //
GLOBENEWSWIRE
Biocartis Highlights Idylla Platform Impact At AMP Conference
17 Nov 2025 //
PHARMIWEB
Biocartis Highlights Idylla Platform Impact At AMP 2025
14 Nov 2025 //
GLOBENEWSWIRE
Biocartis NV Gets FDA Approval for Idylla™ CDx MSI Test
15 Sep 2025 //
GLOBENEWSWIRE
Mike Joins Biocartis as Sr. VP of Global Business Development
19 Aug 2025 //
PHARMAWEB
Biocartis NV appoints Mike as Global Business Development
18 Aug 2025 //
GLOBENEWSWIRE
Biocartis Welcome Ben Svarczkopf as Senior VP of Global Marketing
17 Jun 2025 //
GLOBENEWSWIRE
Biocartis NV Announces IVDR Class C CDx Certification for Idylla
02 Jun 2025 //
GLOBENEWSWIRE
Biocartis NV Launches Brand-New Idylla™ POLE-POLD1 Mutation Assay
02 Apr 2025 //
GLOBENEWSWIRE
Biocartis NV: Multiple Abstracts on Idylla™ Impact at USCAP 2025
18 Mar 2025 //
GLOBENEWSWIRE
Biocartis Unveils CAR-T Vector Load Data At ASTCT Meeting
14 Feb 2025 //
GLOBENEWSWIRE
Biocartis appoints R&y Polonsky as Chief Financial Officer
05 Nov 2024 //
GLOBENEWSWIRE
Biocartis Announces Six Idylla™ Abstracts For AMP 2024
23 Oct 2024 //
GLOBENEWSWIRE
Biocartis Appoints Gina Wallar As CBO, Judith Vacchino As VP Marketing
10 Jun 2024 //
GLOBENEWSWIRE
Biocartis Update On Annual Report Publication, Meeting
09 May 2024 //
GLOBENEWSWIRE
Biocartis & Merck to Collab on Improving Patient Access to Personalized Medicine
07 May 2024 //
PHARMIWEB
Biocartis, Merck Collaborate On Personalized Medicine In MENA
06 May 2024 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
10 Jan 2024 //
GLOBENEWSWIRE
Biocartis Holdings: Recapitalization completed and product portfolio expansion
22 Nov 2023 //
GLOBENEWSWIRE
Biocartis Hosts Corporate Workshop and Announces Seven Idylla
13 Nov 2023 //
GLOBENEWSWIRE
Biocartis Group NV: Announcement regarding Enforcement by Secured Creditors
31 Oct 2023 //
GLOBENEWSWIRE
Biocartis Group NV: Four Abstracts Showing Excellent Data for Idylla
19 Oct 2023 //
GLOBENEWSWIRE
Biocartis Honors Breast Cancer Awareness Month with Launch of Cancer Portfolio
16 Oct 2023 //
GLOBENEWSWIRE
Biocartis Announces Expansion of its Collaboration with APIS Assay Technologies
12 Oct 2023 //
GLOBENEWSWIRE
Press Release Biocartis Group NV: Disclosure of transparency notification
02 Oct 2023 //
GLOBENEWSWIRE
Biocartis announces H1 2023 Results
26 Sep 2023 //
GLOBENEWSWIRE
Biocartis Group: Agreement regarding recapitalization of operating subsidiaries
26 Sep 2023 //
GLOBENEWSWIRE
Biocartis 2023 half-year results webcast on 26 September 2023
20 Sep 2023 //
GLOBENEWSWIRE
Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders
28 Aug 2023 //
GLOBENEWSWIRE
Biocartis Announces 2023 Half-Year Results on 26 September 2023
24 Aug 2023 //
GLOBENEWSWIRE
Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients
10 Aug 2023 //
GLOBENEWSWIRE
Biocartis appoints George Cardoza as new CFO and Head of Service Delivery
18 Jul 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
30 Jun 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
20 Jun 2023 //
GLOBENEWSWIRE
Biocartis announces planned operational reorganization
15 Jun 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
08 Jun 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis announces resignation CFO
05 Jun 2023 //
GLOBENEWSWIRE
Biocartis Group: Results of the Annual Shareholders Meeting held on 12 May 2023
12 May 2023 //
GLOBENEWSWIRE
Biocartis and HiloProbe to Collaborate on Colorectal Cancer Test
09 May 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis Reports Results of 1Q of 2023
20 Apr 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Biocartis appoints Roger Moody as new CEO
11 Apr 2023 //
GLOBENEWSWIRE
Biocartis Announces Publication of 2022 Annual Report
11 Apr 2023 //
GLOBENEWSWIRE
Invitation to the Annual Shareholders Meeting
11 Apr 2023 //
GLOBENEWSWIRE
Biocartis & APIS Assay Sign Collaboration for Subtyping Test on Idylla platform
04 Apr 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
31 Mar 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notification
03 Mar 2023 //
GLOBENEWSWIRE
Biocartis announces the US FDA 510(k) clearance for the Idylla MSI Test
02 Mar 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
28 Feb 2023 //
GLOBENEWSWIRE
Biocartis Creates Share Option Plan and Cancels Outstanding Pool
24 Feb 2023 //
GLOBENEWSWIRE
Biocartis announces 2022 results and 2023 outlook
23 Feb 2023 //
GLOBENEWSWIRE
Biocartis announces change in Board composition
22 Feb 2023 //
GLOBENEWSWIRE
Biocartis Announces 2022 Full Year Results on 23 February 2023
16 Feb 2023 //
GLOBENEWSWIRE
Biocartis Announces the Launch of Assay Developed With the New Idylla Flex Tech
09 Feb 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of Outstanding Voting Securities
31 Jan 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES
17 Jan 2023 //
GLOBENEWSWIRE
Biocartis: Completion of Comprehensive Recapitalization Transactions
16 Jan 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notifications
04 Jan 2023 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Completion of Mandatory Conversion
16 Dec 2022 //
GLOBENEWSWIRE
Press release Biocartis Group NV: Disclosure of transparency notifications
09 Dec 2022 //
GLOBENEWSWIRE
